These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 30049331)

  • 41. Marked heterogeneity of ERG expression in large primary prostate cancers.
    Minner S; Gärtner M; Freudenthaler F; Bauer M; Kluth M; Salomon G; Heinzer H; Graefen M; Bokemeyer C; Simon R; Sauter G; Schlomm T; Wilczak W
    Mod Pathol; 2013 Jan; 26(1):106-16. PubMed ID: 22899295
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Quantitative analysis of ERG expression and its splice isoforms in formalin-fixed, paraffin-embedded prostate cancer samples: association with seminal vesicle invasion and biochemical recurrence.
    Hagen RM; Adamo P; Karamat S; Oxley J; Aning JJ; Gillatt D; Persad R; Ladomery MR; Rhodes A
    Am J Clin Pathol; 2014 Oct; 142(4):533-40. PubMed ID: 25239421
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy.
    Rubio-Briones J; Fernández-Serra A; Calatrava A; García-Casado Z; Rubio L; Bonillo MA; Iborra I; Solsona E; López-Guerrero JA
    J Urol; 2010 May; 183(5):2054-61. PubMed ID: 20303538
    [TBL] [Abstract][Full Text] [Related]  

  • 44. TMPRSS2:ETS fusions and clinicopathologic characteristics of prostate cancer patients from Eastern China.
    Dong J; Xiao L; Sheng L; Xu J; Sun ZQ
    Asian Pac J Cancer Prev; 2014; 15(7):3099-103. PubMed ID: 24815454
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Relation of ETS transcription factor family member ERG, androgen receptor and topoisomerase 2β expression to TMPRSS2-ERG fusion status in prostate cancer.
    Kolar Z; Burdova A; Jamaspishvili T; Bouchal J; Kucerova R; Bienova M; Kral M; Student V
    Neoplasma; 2014; 61(1):9-16. PubMed ID: 24195515
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
    Berg KD
    Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Functional analysis of the TMPRSS2:ERG fusion gene in cisplatin‑induced cell death.
    Wu J; Chi L; Chen Z; Lu X; Xiao S; Zhang G; Luo J; Chen GM; Yang J
    Mol Med Rep; 2016 Apr; 13(4):3173-80. PubMed ID: 26935606
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer.
    Hermans KG; Boormans JL; Gasi D; van Leenders GJ; Jenster G; Verhagen PC; Trapman J
    Clin Cancer Res; 2009 Oct; 15(20):6398-403. PubMed ID: 19825963
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Increased androgen receptor gene copy number is associated with TMPRSS2-ERG rearrangement in prostatic small cell carcinoma.
    Wang L; Williamson SR; Zhang S; Huang J; Montironi R; Davison DD; Wang M; Yao JL; Lopez-Beltran A; Osunkoya AO; MacLennan GT; Baldridge LA; Du X; Cheng L
    Mol Carcinog; 2015 Sep; 54(9):900-7. PubMed ID: 24777847
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High-resolution ERG-expression profiling on GeneChip exon 1.0 ST arrays in primary and castration-resistant prostate cancer.
    Smit FP; Salagierski M; Jannink S; Schalken JA
    BJU Int; 2013 May; 111(5):836-42. PubMed ID: 23578236
    [TBL] [Abstract][Full Text] [Related]  

  • 51. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer.
    Perner S; Demichelis F; Beroukhim R; Schmidt FH; Mosquera JM; Setlur S; Tchinda J; Tomlins SA; Hofer MD; Pienta KG; Kuefer R; Vessella R; Sun XW; Meyerson M; Lee C; Sellers WR; Chinnaiyan AM; Rubin MA
    Cancer Res; 2006 Sep; 66(17):8337-41. PubMed ID: 16951139
    [TBL] [Abstract][Full Text] [Related]  

  • 52. TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate.
    Guo CC; Dancer JY; Wang Y; Aparicio A; Navone NM; Troncoso P; Czerniak BA
    Hum Pathol; 2011 Jan; 42(1):11-7. PubMed ID: 21040948
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antibody-independent targeted quantification of TMPRSS2-ERG fusion protein products in prostate cancer.
    He J; Sun X; Shi T; Schepmoes AA; Fillmore TL; Petyuk VA; Xie F; Zhao R; Gritsenko MA; Yang F; Kitabayashi N; Chae SS; Rubin MA; Siddiqui J; Wei JT; Chinnaiyan AM; Qian WJ; Smith RD; Kagan J; Srivastava S; Rodland KD; Liu T; Camp DG
    Mol Oncol; 2014 Oct; 8(7):1169-80. PubMed ID: 25266362
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model.
    Mertz KD; Setlur SR; Dhanasekaran SM; Demichelis F; Perner S; Tomlins S; Tchinda J; Laxman B; Vessella RL; Beroukhim R; Lee C; Chinnaiyan AM; Rubin MA
    Neoplasia; 2007 Mar; 9(3):200-6. PubMed ID: 17401460
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Relationship between TMPRSS2: ERG and the pathological grade of prostate cancer].
    Yi FX; Li H; Wei Q; Li X; Zeng H
    Zhonghua Nan Ke Xue; 2015 Oct; 21(10):887-91. PubMed ID: 26665675
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer.
    Cai C; Wang H; Xu Y; Chen S; Balk SP
    Cancer Res; 2009 Aug; 69(15):6027-32. PubMed ID: 19584279
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Expressed prostatic secretion biomarkers improve stratification of NCCN active surveillance candidates: performance of secretion capacity and TMPRSS2:ERG models.
    Whelan C; Kawachi M; Smith DD; Linehan J; Babilonia G; Mejia R; Wilson T; Smith SS
    J Urol; 2014 Jan; 191(1):220-6. PubMed ID: 23669563
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The oncogenic gene fusion TMPRSS2: ERG is not a diagnostic or prognostic marker for ovarian cancer.
    Huang L; Schauer IG; Zhang J; Mercado-Uribe I; Deavers MT; Huang J; Liu J
    Int J Clin Exp Pathol; 2011; 4(7):644-50. PubMed ID: 22076164
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antineoplastic Effects of siRNA against TMPRSS2-ERG Junction Oncogene in Prostate Cancer.
    Urbinati G; Ali HM; Rousseau Q; Chapuis H; Desmaële D; Couvreur P; Massaad-Massade L
    PLoS One; 2015; 10(5):e0125277. PubMed ID: 25933120
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fusion between TMPRSS2 and ETS family members (ERG, ETV1, ETV4) in prostate cancers from northern China.
    Wang JJ; Liu YX; Wang W; Yan W; Zheng YP; Qiao LD; Liu D; Chen S
    Asian Pac J Cancer Prev; 2012; 13(10):4935-8. PubMed ID: 23244085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.